We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation
News

Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation

Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation
News

Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scaffdex Oy and Conmed Linvatec Biomaterials have signed a licensing agreement of commercialization and clinical data of joint prosthesis innovation. Target of Scaffdex Oy is CE marking and launch of this product by end of 2010.
Joint prosthesis replaces small joints in hand and foot and it has been tested clinically for example in rheumatoid arthritis patients. Tampere University Hospital, Hospital of Foundation of Rheumatoid Arthritis in Heinola and clinics in Germany and Italy participated these international clinical trials.
Advertisement